mir-515 inhibitor sensitizes HER2-negative breast and liver cancers to Kadcyla, Herceptin

DISEASE CATEGORY: Cancer

INDICATION: Breast cancer; liver cancer

In vitro and cell culture studies suggest an inhibitor of miR-515 could sensitize HER2-negative

Read the full 209 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE